Publicaciones en colaboración con investigadores/as de Mutua de Terrassa (16)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

2022

  1. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications

    Histopathology, Vol. 81, Núm. 6, pp. 826-840

  2. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  3. Sex and substance use in first episode psychosis: Impact on clinical symptoms, psychosocial functioning and cognitive performance

    Revista de Psiquiatria y Salud Mental

2021

  1. Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials)

    Journal of Autism and Developmental Disorders, Vol. 51, Núm. 8, pp. 2959-2972

  2. Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) (Journal of Autism and Developmental Disorders, (2021), 51, 8, (2959-2972), 10.1007/s10803-020-04709-8)

    Journal of Autism and Developmental Disorders

  3. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation

    BMC Cardiovascular Disorders, Vol. 21, Núm. 1

2018

  1. Candida periprosthetic joint infection: A rare and difficult-to-treat infection

    Journal of Infection, Vol. 77, Núm. 2, pp. 151-157

2017

  1. The not-so-good prognosis of streptococcal periprosthetic joint infection managed by implant retention: The results of a large multicenter study

    Clinical Infectious Diseases, Vol. 64, Núm. 12, pp. 1742-1752

2014

  1. Cluster-randomized, controlled 12-month trial to evaluate the effect of a parental psychoeducation program on medication persistence in children with attention-defcit/hyperactivity disorder

    Neuropsychiatric Disease and Treatment, Vol. 10, pp. 1081-1092

2011

  1. Composite anatomical-clinical-molecular prognostic model in nonsmall cell lung cancer

    European Respiratory Journal, Vol. 37, Núm. 1, pp. 136-142

2005

  1. Safety and effectiveness of olanzapine in monotherapy: A multivariate analysis of a naturalistic study

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 29, Núm. 6, pp. 944-951

  2. Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: A multivariate analysis of a large naturalistic study in the hospital setting

    Medicina Clinica, Vol. 124, Núm. 13, pp. 481-486

2003

  1. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 27, Núm. 3, pp. 473-481

  2. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study

    European Neuropsychopharmacology, Vol. 13, Núm. 1, pp. 39-48

2001

  1. Incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone: Results of an observational study (EFESO study)

    Actas Espanolas de Psiquiatria, Vol. 29, Núm. 1, pp. 25-32